Cell Rep:新型抗体或可靶向作用HIV的防御保护性缺口结构

2016-09-14 佚名 生物谷

近日,发表在国际杂志Cell Reports上的一篇研究报告中,来自斯克利普斯研究所的研究人员通过研究揭示了HIV防御性糖类“盾牌”的缺口结构,或为开发新型HIV疫苗提供新的思路。研究者指出,基于本文研究结果,他们就能够开发出靶向作用这些缺口结构的抗体,而这些缺口结构分散在HIV的保护性糖类外壳上(聚糖外壳),于是研究者就像深入探究是否这些缺口结构能够被开发来诱导保护性抗体的产生。 研究者Den

近日,发表在国际杂志Cell Reports上的一篇研究报告中,来自斯克利普斯研究所的研究人员通过研究揭示了HIV防御性糖类“盾牌”的缺口结构,或为开发新型HIV疫苗提供新的思路。研究者指出,基于本文研究结果,他们就能够开发出靶向作用这些缺口结构的抗体,而这些缺口结构分散在HIV的保护性糖类外壳上(聚糖外壳),于是研究者就像深入探究是否这些缺口结构能够被开发来诱导保护性抗体的产生。

研究者Dennis R. Burton教授表示,如今评估候选疫苗的功效对于我们快速理解疫苗所有到的机体免疫反应非常重要。每种病毒都有着特殊的结构特性,就好象建筑物的结构一样,通过解析这些结构特征,科学家们就能够绘制出蓝图来阐明HIV的哪些部位对于阻断感染的抗体非常敏感。20世纪90年代,科学家们发现,HIV能够在其聚糖分子的保护性外壳结构上随机产生缺口结构,然而直到现在为止,研究者们依然并不清楚是否抗体能够识别并且靶向作用这些缺口结构。

此前康奈尔大学和斯克利普斯研究所的研究人员通过联合研究设计了一种稳定形式的HIV蛋白,名为包膜糖蛋白(Env)三聚体,该蛋白能够促进兔子模型产生抵御HIV的抗体,而在本文研究中研究者计划通过检测抗体结合病毒的位点来阐明HIV的脆弱点。研究者Laura McCoy表示,通过对HIV阳性的个体进行研究我们发现,理解机体抗体反应的最好方法就是分离出单一的抗体并对其进行深入研究。

让研究者非常好奇的是,当他们检测兔子机体的抗体时他们发现,三只兔子能够产生靶向作用HIV包膜糖蛋白中相同缺口的抗体,这就表明,这些抗体的确能够靶向作用HIV聚糖保护性外壳中的缺口结构,这或许就为科学家们打开了设计新型疫苗的方法。研究者指出,如果机体免疫系统能够靶向作用这种缺口,或者说相比其它包膜糖蛋白的易感位点而言更喜欢这种缺口,那么这些特殊的缺口结构或许就对科学家们日后设计新型HIV疫苗会带来一定的希望。

通过分析数千个HIV毒株的遗传序列,研究者发现,89%的HIV毒株都在包膜糖蛋白上存在靶向性的缺口结构,尽管HIV有着防御性的机制,能够快速突变来填补这些缺口;研究者们推测,未来开发的疫苗或许能够刺激免疫系统产生靶向作用这种缺口结构的抗体,而靶向作用缺口结构则能够帮助机体免疫系统迈出抗病毒的第一步。

最后研究者Burton表示,我们必须调查不同的可能性,但本文对于HIV聚糖缺口结构的研究获奖帮助我们开发新型的HIV疫苗设计策略;科学家们通常利用病毒的精细分子细节来促进机体免疫系统产生特殊抗体,而利用相同的方法研究者或许不仅能够开发出抵御HIV的疫苗,还能够开发出抵御其它病毒的疫苗,比如流感病毒和埃博拉病毒的疫苗。

原始出处

Laura E. McCoy9, Marit J. van Gils9, Gabriel Ozorowski9, Terrence Messmer, Bryan Briney, James E. Voss, Daniel W. Kulp, Matthew S. Macauley, Devin Sok, Matthias Pauthner, Sergey Menis, Christopher A. Cottrell, Jonathan L. Torres, Jessica Hsueh, William R. Schief, Ian A. Wilson, Andrew B. Ward, Rogier W. Sanders, Dennis R. Burton10.Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies.Cell Rep.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959802, encodeId=89ef195980292, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 22 03:06:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950753, encodeId=cf631950e537c, content=<a href='/topic/show?id=9b0c99894af' target=_blank style='color:#2F92EE;'>#靶向作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99894, encryptionId=9b0c99894af, topicName=靶向作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Wed Jan 18 06:06:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869543, encodeId=f1a2186954321, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Aug 14 17:06:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128036, encodeId=14ad128036b0, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 17:38:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127781, encodeId=bd6812e78197, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 15:34:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127662, encodeId=cb0f12e6624e, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 14:52:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126965, encodeId=01dc126965a9, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 22:03:00 CST 2016, time=2016-09-14, status=1, ipAttribution=)]
    2016-11-22 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959802, encodeId=89ef195980292, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 22 03:06:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950753, encodeId=cf631950e537c, content=<a href='/topic/show?id=9b0c99894af' target=_blank style='color:#2F92EE;'>#靶向作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99894, encryptionId=9b0c99894af, topicName=靶向作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Wed Jan 18 06:06:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869543, encodeId=f1a2186954321, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Aug 14 17:06:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128036, encodeId=14ad128036b0, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 17:38:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127781, encodeId=bd6812e78197, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 15:34:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127662, encodeId=cb0f12e6624e, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 14:52:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126965, encodeId=01dc126965a9, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 22:03:00 CST 2016, time=2016-09-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959802, encodeId=89ef195980292, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 22 03:06:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950753, encodeId=cf631950e537c, content=<a href='/topic/show?id=9b0c99894af' target=_blank style='color:#2F92EE;'>#靶向作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99894, encryptionId=9b0c99894af, topicName=靶向作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Wed Jan 18 06:06:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869543, encodeId=f1a2186954321, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Aug 14 17:06:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128036, encodeId=14ad128036b0, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 17:38:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127781, encodeId=bd6812e78197, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 15:34:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127662, encodeId=cb0f12e6624e, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 14:52:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126965, encodeId=01dc126965a9, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 22:03:00 CST 2016, time=2016-09-14, status=1, ipAttribution=)]
    2017-08-14 仁医06
  4. [GetPortalCommentsPageByObjectIdResponse(id=1959802, encodeId=89ef195980292, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 22 03:06:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950753, encodeId=cf631950e537c, content=<a href='/topic/show?id=9b0c99894af' target=_blank style='color:#2F92EE;'>#靶向作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99894, encryptionId=9b0c99894af, topicName=靶向作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Wed Jan 18 06:06:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869543, encodeId=f1a2186954321, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Aug 14 17:06:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128036, encodeId=14ad128036b0, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 17:38:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127781, encodeId=bd6812e78197, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 15:34:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127662, encodeId=cb0f12e6624e, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 14:52:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126965, encodeId=01dc126965a9, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 22:03:00 CST 2016, time=2016-09-14, status=1, ipAttribution=)]
    2016-09-15 1dd8a7c5m95(暂无匿称)

    学习了,赞一个!!!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1959802, encodeId=89ef195980292, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 22 03:06:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950753, encodeId=cf631950e537c, content=<a href='/topic/show?id=9b0c99894af' target=_blank style='color:#2F92EE;'>#靶向作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99894, encryptionId=9b0c99894af, topicName=靶向作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Wed Jan 18 06:06:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869543, encodeId=f1a2186954321, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Aug 14 17:06:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128036, encodeId=14ad128036b0, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 17:38:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127781, encodeId=bd6812e78197, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 15:34:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127662, encodeId=cb0f12e6624e, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 14:52:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126965, encodeId=01dc126965a9, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 22:03:00 CST 2016, time=2016-09-14, status=1, ipAttribution=)]
    2016-09-15 1dd8a7c5m95(暂无匿称)

    学习了,赞一个!!!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1959802, encodeId=89ef195980292, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 22 03:06:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950753, encodeId=cf631950e537c, content=<a href='/topic/show?id=9b0c99894af' target=_blank style='color:#2F92EE;'>#靶向作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99894, encryptionId=9b0c99894af, topicName=靶向作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Wed Jan 18 06:06:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869543, encodeId=f1a2186954321, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Aug 14 17:06:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128036, encodeId=14ad128036b0, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 17:38:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127781, encodeId=bd6812e78197, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 15:34:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127662, encodeId=cb0f12e6624e, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 14:52:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126965, encodeId=01dc126965a9, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 22:03:00 CST 2016, time=2016-09-14, status=1, ipAttribution=)]
    2016-09-15 1dd8a7c5m95(暂无匿称)

    学习了,赞一个!!!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1959802, encodeId=89ef195980292, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 22 03:06:00 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950753, encodeId=cf631950e537c, content=<a href='/topic/show?id=9b0c99894af' target=_blank style='color:#2F92EE;'>#靶向作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99894, encryptionId=9b0c99894af, topicName=靶向作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Wed Jan 18 06:06:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869543, encodeId=f1a2186954321, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Aug 14 17:06:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128036, encodeId=14ad128036b0, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 17:38:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127781, encodeId=bd6812e78197, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 15:34:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=127662, encodeId=cb0f12e6624e, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Thu Sep 15 14:52:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126965, encodeId=01dc126965a9, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Wed Sep 14 22:03:00 CST 2016, time=2016-09-14, status=1, ipAttribution=)]
    2016-09-14 1dd8a7c5m95(暂无匿称)

    学习了,赞一个!!!

    0

相关资讯

Nature:从原子水平揭示为何HIV能够逃避免疫系统检测

来自英国医学研究委员会(MRC)分子生物学实验室和伦敦大学学院的研究人员发现HIV用来感染细胞同时逃避免疫系统检测的一种关键特征。这一发现提供一种新的药物靶标和重新评估现存HIV疗法以便改善它们的疗效的机会。相关研究结果于2016年8月10日在线发表在Nature期刊上,论文标题为“HIV-1 uses dynamic capsid pores to import nucleotides and

吉利德支持Genmab开发双特异性抗体治疗HIV

制药巨头吉利德公司最近宣布和丹麦生物技术公司Genmab达成了一项合作协议,利用后者开发的双特异性抗体技术平台开发治疗HIV的特效药物。按照协议,吉利德公司将获得Genmab公司专利技术的独家授权开发新型HIV疗法。此外,公司还有权开发另一种疾病的双特异性抗体药物。但两家公司均未透露第二种药物靶点信息。 作为回报,吉利德公司将向Genmab公司支付最高超过3亿美元的经费。这其中包括了

2015BHIVA指南——HIV阳性成人使用疫苗发布

2016年8月,英国艾滋病协会(BHIVA)发布了HIV阳性成人使用疫苗指南,本文提供了更新的基于GRADE分级的HIV阳性成人使用疫苗建议。更新部分包括HPV疫苗,带状疱疹疫苗和肺炎球菌疫苗的应用,针对乙型肝炎,脑膜炎球菌和百日咳疫苗进行了更进一步的关键信息更新。全文获取:下载地址:指南下载 (需要扣积分2分, 梅斯医学APP免积分下载)

PLOS Med:放心啪啪啪?ART联合PrEP可近100%的阻止HIV的传播

随机临床试验中基于抗逆转录病毒以预防HIV-1传播的疗法,包括抗逆转录病毒疗法(ART)来减少HIV-1感染者和暴露前预防(PrEP)来降低HIV-1未感染者的易感性,显示了较高的疗效。该研究进行了一项前瞻性实验研究以探究这些干预措施在分娩环境中的可行性和有效性。 2012年1月5日至2015年11月5日,研究人员招募并随访了1013对来自肯尼亚和乌干达的HIV-血清异质性夫妇进行此前瞻性研

PLoS Pathog:对HIV广谱中和抗体进行工程化操作制造出更好的疫苗

开发HIV疫苗的一种方法依赖于可以抵御不同循环HIV的广谱中和抗体(broadly neutralizing antibodies, bnAbs),这种抗体分离自感染HIV的个体机体中,但其却是高度进化且不寻常的抗体;近日一项刊登在国际杂志PLoS Pathogens上的研究报告中,来自斯克利普斯研究所等机构的科学家报道了一种鉴别bnAbs必要特征的新方法,同时研究者还提出了一些更适合于开发新型的